BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

Read more:
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Read the original post:
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

See the original post here:
CytoDyn Announces Appointment of Additional Directors with Industry Experience

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

Go here to read the rest:
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

See original here:
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

Revenue on September 30, 2022

Read more here:
Guerbet: Revenue at September 30, 2022

Idorsia will publish its financial results for the first nine months of 2022 on October 25, 2022, at 07:00 CEST.

See the rest here:
Invitation to Idorsia's nine-month financial results 2022 webcast and conference call

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary General Meeting (AGE) held on October 17, 2022 has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favorable to, i.e. 10 out of the 11 resolutions.

Follow this link:
DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM)

More here:
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time

View post:
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast